Kairos Announces Positive Interim Phase 1 ENV-105 Data
LOS ANGELES, July 15, 2026 Kairos Pharma announced encouraging interim safety results from its ongoing Phase 1 clinical trial...
AstraZeneca
Advertisement
Dizal Licenses Zegfrovy to AstraZeneca in $1.5B Deal
SHANGHAI, China, July 14, 2026 Dizal has entered into a landmark global exclusive license agreement with AstraZeneca for Zegfrovy...
AstraZeneca Reports Wainua Phase III ATTR-CM Trial Results
CAMBRIDGE, United Kingdom, July 9, 2026 AstraZeneca and Ionis Pharmaceuticals have announced results from the Phase III CARDIO-TTRansform trial...
Sino Biopharm Secures $2.1B TQC3721 AstraZeneca Agreement
HONG KONG, July 8, 2026 Sino Biopharmaceutical Limited has announced that its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co.,...
CSPC Pharma Secures Up to $1.77B AstraZeneca siRNA Deal
HONG KONG, July 2, 2026 CSPC Pharmaceutical Group Limited has announced a strategic collaboration, option and license agreement with...
Advertisements
Abbisko and AstraZeneca Advance Oral PD-L1 Therapy for NSCLC
SHANGHAI, China, July 1, 2026 Abbisko Therapeutics and AstraZeneca have entered into a strategic collaboration to advance the clinical...
HUTCHMED Wins NMPA Approval for ORPATHYS® in Gastric Cancer
Hong Kong, Shanghai & Florham Park, N.J., July 2, 2026 HUTCHMED has achieved a major regulatory milestone after the...
Daiichi Sankyo and AstraZeneca Secure EU Enhertu Approval
TOKYO, June 29, 2026 Daiichi Sankyo and AstraZeneca have announced that the European Commission (EC) has approved Enhertu® (trastuzumab...
AstraZeneca, Daiichi Sankyo Advance Datroway Toward EU Approval
CAMBRIDGE, UK & TOKYO, Japan, June 26, 2026 AstraZeneca and Daiichi Sankyo have moved one step closer to expanding...
AIM ImmunoTech Advances Ampligen Toward Potential Pivotal Development
OCALA, Fla., June 24, 2026 AIM ImmunoTech Inc. highlighted significant progress across its pancreatic cancer development program, positioning Ampligen®...
Advertisement
